Review of Palliative Ra in Metastatic Castration-Resistant Prostate Cancer: Experience at West Virginia University Cancer Center.

The ALSYMPCA trial of the α-emitter Ra in symptomatic bone-predominant metastatic castration-resistant prostate cancer (mCRPC) reported a median overall survival (OS) of 14.9 mo, versus 11.3 mo for placebo.